Recent studies have unveiled intriguing connections between GLP-1 medications and a decreased likelihood of certain cancers, coinciding with the increasing availability and affordability of semaglutide in Canadian pharmacies. As generics begin to emerge in the market this year, medical professionals and researchers are taking note of the potential implications for cancer prevention. These findings were presented at the American Society of Clinical Oncology meeting in Chicago, where over two dozen studies highlighted the promising benefits of GLP-1 drugs, particularly in relation to cancer risk and treatment efficacy.
Groundbreaking Findings in Cancer Research
The latest research draws attention to the significant role that GLP-1 medications, traditionally prescribed for Type 2 diabetes, may play in cancer prevention. Dr. Judith Bray, vice-president of research at the Canadian Cancer Society, expressed optimism regarding the transformative potential of these findings. “These rumbling or smoking guns have been firing off for well over a year now about this possibility,” she noted, adding that the research community is now actively engaged in exploring these links.
One pivotal study conducted by researchers from the ESMO Annals of Oncology analysed data from over 161,000 patients, primarily those classified as obese and without a prior diagnosis of obesity-related cancer. Among these participants, one group received GLP-1 weight-loss injections, while the other engaged in standard dietary and exercise consultations. The results were striking: individuals on GLP-1 medications exhibited a remarkable 41 per cent reduction in the risk of being diagnosed with obesity-related cancers during the two-year follow-up.
Insights into Breast Cancer Prevention
Further investigation into the potential benefits of GLP-1 medications revealed a link with lower breast cancer incidence. A recent study published in JCO Oncology Practice found that GLP-1 treatment correlated with a decreased breast cancer risk, independent of factors such as age, race, ethnicity, BMI, and breast density. The study tracked over 110,000 patients aged 45 to 80 who underwent breast imaging between January 2022 and June 2025, highlighting that nearly 14 per cent had been prescribed GLP-1 drugs.
The findings indicated that women using these medications could face up to a 35 per cent lower risk of developing breast cancer compared to those not on GLP-1 therapies. Researchers further corroborated these results by matching over 15,000 women on GLP-1 drugs with similar women who were not, discovering that the former had nearly 31 per cent lower odds of being diagnosed with the disease. Lead researcher Dr. Elizabeth McDonald emphasised that while the study is observational and does not confirm a definitive association, it adds to the growing body of evidence suggesting that these weight-loss medications warrant further exploration as potential cancer prevention tools.
The Broader Implications for Canadian Health
With Statistics Canada reporting that 68 per cent of Canadian adults aged 18 to 79 had a body mass index (BMI) classified as overweight or obese from 2022 to 2024—an increase from 60 per cent prior to the COVID-19 pandemic—the implications of these findings become even more critical. Breast cancer is projected to be the most commonly diagnosed cancer among women in Canada by 2026, underscoring the urgency for innovative preventive measures.
Kimberly Carson, CEO of Breast Cancer Canada, expressed enthusiasm about the research, calling it “very encouraging” and a hopeful sign for future developments in cancer prevention strategies. Carson advocates for additional Canadian studies in this area, recognising the country’s potential to contribute valuable data to the ongoing discourse on GLP-1 medications and cancer risk.
Why it Matters
As the landscape of cancer treatment and prevention evolves, the promising connections between GLP-1 drugs and reduced cancer risks could represent a significant breakthrough in public health. With rising obesity rates and the anticipated increase in breast cancer diagnoses, identifying effective preventive measures is paramount. The potential for GLP-1 medications to serve not only as weight-loss solutions but also as tools for cancer prevention highlights the need for continued research and investment in this promising area. As the medical community rallies to further investigate these findings, the hope is that we may soon unlock new strategies to combat cancer and improve the health outcomes of countless individuals.
